Triptan use in Australia 1997‐2015: A pharmacoepidemiological study
The use of medicines for treating migraine attacks has been explored in several countries and regions,1 but there has been no comprehensive published study of antimigraine medicine use in Australia. Most therapeutic medicine use in Australia is subsidized through two schemes. The Pharmaceutical Benefits Scheme (PBS) is a national formulary of subsidized prescription medicines available to all Australian citizens and permanent residents.13 The Repatriation Pharmaceutical Benefits Scheme (RPBS) covers service personnel and dependents and provides a slightly more extensive range of medicines. The marketed agents subsidized as migraine‐specific acute medicines during the period covered in this study were almost exclusively triptan derivatives: sumatriptan tablets, nasal sprays, and fast dissolving tablets; zolmitriptan and naratriptan tablets (all available throughout the study period); eletriptan tablets (available since March 2010); and rizatriptan wafers and fast dissolving tablets (since October 2010 and December 2015, respectively). We here aim to describe the dispensed use of these subsidized triptan derivatives in Australia between 2003 and 2015. Triptans in Australia are subsidized only for treating migraine attacks and in clinical practice do not appear to be employed for other indications.